Google Cloud has unveiled two new artificial intelligence (AI) tool suites, already adopted by firms like Pfizer and Colossal Biosciences, aimed at enhancing drug discovery and precision medicine. The Target and Lead Identification Suite assist in protein structure prediction, while the Multiomics Suite focuses on genomic data interpretation and precision therapeutic development.
Google Cloud has launched two novel suites of artificial intelligence (AI) tools, which are already being utilized by pharma and biotech companies, such as Pfizer and Colossal Biosciences. Introduced at the Bio-IT World Conference and Expo in Boston, these technologies are designed to foster progress in precision medicine and drug discovery.
The Target and Lead Identification Suite is geared towards aiding pharmaceutical researchers in understanding the function of amino acids and predicting protein structures. The suite also offers AI-enabled data management and sharing capabilities, leveraging Google’s AlphaFold2 and Vertex AI data pipelines for more precise protein structure prediction.
The Multiomics Suite is tailored for discovering and interpreting genomic data, assisting in the development and deployment of precision therapeutics. The suite streamlines the management and sharing of data, providing secure exchange options and raw sequence file management. The tools can also accelerate processing and help identify genes associated with specific diseases or traits.
Considering the high costs and lengthy timelines associated with drug development, and the continuous doubling of genomic data volume, Google Cloud’s new suites aim to facilitate the process. Shweta Maniar, the director of Healthcare and Life Sciences industry solutions at Google Cloud, emphasizes the importance of AI and machine learning advancements in this endeavor.
She highlighted the significant role of generative AI, which is capable of creating new information based on probabilistic analysis and specialized computing. With numerous complexities still to be understood in the “Code of Life“, Maniar envisions AI as a critical tool for uncovering these puzzles.
Endorsements of these tools came from industry leaders. Claude Barberis, Vice President of Medicinal Chemistry at Cerevel, praised “The Target and Lead Identification Suite” for its efficiency in discovery efforts. Dr. Alexander Titus, Vice President of Strategy and Computational Sciences at Colossal Biosciences, highlighted that the “Multiomics Suite” led to a 52% cost reduction and an 88% reduction in time for whole genome sequence analysis, enhancing overall computational efficiency.
